Integrated molecular and clinical staging defines the spectrum of metastatic cancer
综合分子和临床分期定义了转移性癌症的范围
摘要：
The elimination of metastases remains one of the major challenges in the curative treatment of patients with cancer.Therefore, most patients with metastatic disease typically receive systemic agents, which prolong survival and alleviate symptoms but are rarely curative.The oligometastatic paradigm challenges the prevailing view of metastasis as a disseminated process and proposes the existence of a spectrum of biological virulence within metastatic lesions.In this Perspectives article, we present evidence supporting our hypothesis that integrated clinical and molecular classification of metastases along the spectrum of disease influences the staging and treatment of patients with cancer.
消除转移仍然是癌症患者的治愈性治疗中的主要挑战之一。因此，大多数患有转移性疾病的患者通常接受全身性药物，其延长存活期并缓解症状但很少治愈。低转移范式挑战了转移作为传播过程的普遍观点，并提出在转移性病变中存在一系列生物毒力。在这篇Perspectives文章中，我们提出证据支持我们的假设，即疾病谱中转移的综合临床和分子分类会影响癌症患者的分期和治疗。